BLFE — Biolife Sciences Share Price
Last trade - 00:00- $0.00m
- $0.29m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Nov | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.41 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioLife Sciences Inc. is a commercialization accelerator, licensor, and disruptive technologies for the healthcare, beauty, and food and beverage industry sectors. The Company's core business develops, licenses and distributes antimicrobial products and disruptive technology. Its solutions include Copper-Infused Textiles and Copper Infused Fabric Pots. Its BioLife antimicrobial copper fabric filter acts as a layer of protection by trapping in bacteria and releasing clean air. BioLife Antimicrobial Copper-Infused Textiles kill viruses and bacteria on contact through preventative clothing and textiles designed to inhibit virus and bacteria reproduction and cross contamination before it starts. Its BioLife Copper Infused Fabric Pots provides healthier plant growth. The copper infusion allows the plants that grow in the pots with additional protections from harmful microbes which can harm plants.
Directors
- Justin De Four CHM
- John Rudy CFO (69)
- Lloyd Glick COO (70)
- Arthur Viola SEC (70)
- Nataliya Hearn DRC (46)
- Brian Morales DRC
- Last Annual
- November 30th, 2021
- Last Interim
- November 30th, 2012
- Incorporated
- March 31st, 2000
- Public Since
- April 25th, 2005
- No. of Employees
- 565
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 3,183,485,768
- Address
- 2831 Saint Rose Parkway, Suite 200, HENDERSON, 89052
- Web
- https://www.biolifesciences.com/
- Phone
- +1 7028662500
- Auditors
- Unaudited
Similar to BLFE
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 19:35 UTC, shares in Biolife Sciences are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Biolife Sciences last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Biolife Sciences share price has underperformed the S&P500 Index by -6.57% over the past year.
There is no consensus recommendation for this security.
Find out moreBiolife Sciences does not currently pay a dividend.
Biolife Sciences does not currently pay a dividend.
Biolife Sciences does not currently pay a dividend.
To buy shares in Biolife Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Biolife Sciences had a market capitalisation of $0.00m.
Here are the trading details for Biolife Sciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BLFE
Based on an overall assessment of its quality, value and momentum Biolife Sciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biolife Sciences. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in Biolife Sciences were trading -98.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biolife Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biolife Sciences' management team is headed by:
- Justin De Four - CHM
- John Rudy - CFO
- Lloyd Glick - COO
- Arthur Viola - SEC
- Nataliya Hearn - DRC
- Brian Morales - DRC